Kaplan-Meier curve showing a statistically significant delay in type 1 diabetes onset for persons treated with teplizumab-treatment compared to persons treated with a placebo.

FIGURE 2.

TrialNet Teplizumab Trial in At-Risk Relatives Demonstrates Significant Delay in Diabetes Onset Compared to Placebo.

Updated Kaplan-Meier Curve based on 923 days of follow-up (range 74–3,119 days). The hazard ratio for development of type 1 diabetes in teplizumab-treated participants versus placebo was 0.457 (p=0.01). The median time to diabetes was 27.1 and 59.6 months in the placebo and teplizumab treatment groups, respectively. At the conclusion of this period, 7 (22%) and 22 (50%) participants, respectively, were not diagnosed with type 1 diabetes. T1D, type 1 diabetes.

SOURCE: Reference (97), reprinted with permission

From: Prevention of Type 1 Diabetes

Cover of Diabetes in America
Diabetes in America [Internet].
Lawrence JM, Casagrande SS, Herman WH, et al., editors.
Copyright Notice

Diabetes in America is in the public domain of the United States. You may use the work without restriction in the United States.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.